We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.

Delisted

BLPH was delisted on the 13th of October, 2023.

22 hedge funds and large institutions have $4.81M invested in Bellerophon Therapeutics, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% less funds holding

Funds holding: 2722 (-5)

24% less capital invested

Capital invested by funds: $6.34M → $4.81M (-$1.53M)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
22
Holders Change
-5
Holders Change %
-18.52%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
6
Reduced
10
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
-$2.77K -666 -90%

BLPH Hedge Fund Activity: Q3 2021 in Review

22 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2021, worth a combined $4.81M — down 24% from $6.34M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BLPH and 1 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Group, adding an estimated $18.7K. The largest seller was Renaissance Technologies, cutting an estimated $231K.

  • 22 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2021, down from 27 in Q2 2021.
  • Funds reported $4.81M of Bellerophon Therapeutics, Inc. stock for Q3 2021, down 24% quarter-over-quarter.
  • 1 fund opened new Bellerophon Therapeutics, Inc. positions in Q3 2021 and 6 closed out, a net change of -5 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q3 2021 was Vanguard Group, an estimated $18.7K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q3 2021 was Renaissance Technologies, an estimated $231K sold.

Based on aggregated 13F filings for Q3 2021.